Phase 1 Advanced Unresectable Clinical Trials
12 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–12 of 12 trials
Recruiting
Phase 1
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
Advanced Unresectable Hepatocellular Carcinoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.36 enrolled2 locationsNCT07478302
Recruiting
Phase 1Phase 2
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
MetastaticAdvanced Unresectable
Beijing Biotech72 enrolled1 locationNCT07523529
Recruiting
Phase 1Phase 2
A Study of HRS-6208 in Combination With HRS-8080, or Fulvestrant, or Letrozole, With or Without HRS-6209 in Patients With Advanced Unresectable or Metastatic Breast Cancer
Advanced Unresectable or Metastatic Breast Cancer of Adults
Shandong Suncadia Medicine Co., Ltd.180 enrolled2 locationsNCT07389733
Recruiting
Phase 1Phase 2
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma+97 more
Mayo Clinic132 enrolled1 locationNCT05269381
Recruiting
Phase 1Phase 2
A Trial of HRS-2189 in Combination With Fluvastatin±HRS-6209, or HRS-8080±HRS-6209, or HRS-6209+HRS-1358 in Breast Cancer Patients
Advanced Unresectable or Metastatic Breast Cancer
Shandong Suncadia Medicine Co., Ltd.300 enrolled2 locationsNCT06679036
Recruiting
Phase 1
Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma
Locally Advanced Unresectable Pancreatic Adenocarcinoma
Impact Biotech Ltd30 enrolled2 locationsNCT05919238
Recruiting
Phase 1
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
Solid TumorsMetastatic Hepatocellular CarcinomaAdvanced Solid Tumors+11 more
Tyra Biosciences, Inc100 enrolled16 locationsNCT06915753
Recruiting
Phase 1
A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.470 enrolled39 locationsNCT05458219
Recruiting
Phase 1
SG1906 for CLDN18.2-Positive Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.60 enrolled9 locationsNCT05857332
Recruiting
Phase 1Phase 2
A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients
Advanced Unresectable or Metastatic Breast Cancer
Jiangsu HengRui Medicine Co., Ltd.528 enrolled1 locationNCT06555068
Recruiting
Phase 1Phase 2
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Locally Advanced Unresectable or Metastatic Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.368 enrolled6 locationsNCT05636215
Recruiting
Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
Metastatic Solid TumorAdvanced Unresectable Solid Tumor
TopAlliance Biosciences499 enrolled24 locationsNCT04137900